Luf

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Luf

Luf is a trade name for a medication whose sole active ingredient is Flucloxacillin, typically supplied as the Sodium salt. This substance is classified as a Beta-lactam antibiotic, belonging to the larger family of penicillins.


Property Description
Active Ingredient Flucloxacillin (Sodium)
Form Capsules, Oral Liquid, Powder for Injection
Pharmacological Class Beta-lactam Antibiotic
General Purpose To kill susceptible bacteria (Bactericidal)
Origin Semisynthetic (Chemically derived penicillin)

Luf: Identity and Classification as an Antibiotic

Luf is a prescription-only medicine that contains the active ingredient Flucloxacillin and is recognized within the medical community as a semisynthetic isoxazolyl penicillin. This classification places it firmly within the group of Beta-lactam antibiotics. The unique semisynthetic nature of Flucloxacillin ensures the drug is acid-stable, a property that facilitates effective systemic absorption when administered by the oral route.

The Distinction of Flucloxacillin: Resistance and General Purpose

The medication is supplied in various pharmaceutical preparations, including capsules and an oral liquid medicine suitable for children or patients with swallowing difficulty, as well as powder for injection for parenteral route use. The fundamental general purpose of this substance is to combat bacterial infections via a bactericidal effect, meaning the drug directly kills the target bacteria.

A key defining feature is its classification as a penicillinase-resistant penicillin. This characteristic is clinically recognized as essential because it enables the drug to withstand the destructive action of the beta-lactamase enzyme produced by certain resistant bacteria. This specialized resistance ensures that Luf remains an effective option for infections caused by sensitive Gram-positive organisms that might inactivate other penicillins.

What side effects are possible with Luf?

Possible Side Effects and Safety Information

The safety profile of Luf (Flucloxacillin) is formally classified by regulatory authorities based on the frequency and type of adverse reactions observed. The reactions fall into defined system-organ classes, with specific focus on hypersensitivity and hepatobiliary (liver) events.

Frequency-Classified Adverse Reactions

Adverse reactions are documented by official frequency categories:

  • Common: Includes minor gastrointestinal disturbances, such as nausea and diarrhoea.
  • Uncommon: Typically involves skin and subcutaneous tissue disorders, such as rash and urticaria.
  • Very Rare: Covers severe systemic reactions like anaphylactic shock, hepatitis, cholestatic jaundice, and blood disorders (e.g., neutropenia). Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented in this category.

Serious Safety Considerations

Regulatory documentation highlights serious reactions related to the Immune System and Hepatobiliary System. The onset of severe hepatic reactions, such as hepatitis and cholestatic jaundice, may be delayed for up to two months after treatment is complete. These reactions are associated with an increased risk in older adults (especially over 50 years) and those receiving prolonged treatment.

The medicine is officially restricted in individuals with a known history of hypersensitivity to beta-lactam antibiotics (penicillins or cephalosporins) or a prior history of Flucloxacillin-associated jaundice or hepatic dysfunction. For patients undergoing prolonged use, monitoring of hepatic and renal functions is recommended in the regulatory documentation.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation specifies that an overdose of Luf (Flucloxacillin) or exposure to very high doses is associated with a range of acute manifestations across several body systems. Documented symptoms may include general gastrointestinal disturbances such as nausea, vomiting, and diarrhoea.

More severe manifestations are linked to high parenteral doses, involving the central nervous system (CNS) with reported neurotoxicity, convulsions, and encephalopathy. High-dose exposure can also lead to haematological issues, including blood disorders and haemolytic anaemia, alongside electrolyte disturbances such as hypokalaemia, which is classified as potentially life-threatening.

Urgent Help-Seeking Requirements

Immediate emergency action is mandated in all cases of suspected overdose. Official regulatory guidance requires that a doctor or National Poisons Centre be contacted right away, and the patient must proceed immediately to the nearest accident and emergency department. This mandatory action applies even if the patient exhibits no immediate signs of discomfort or poisoning.

Management and Risk Factors

No specific antidote for Flucloxacillin overdose is known; therefore, the treatment focuses entirely on symptomatic and supportive care. Regular monitoring of potassium levels, hepatic function, and renal function is explicitly recommended during high-dose exposure. Special caution is also noted for patients with impaired renal function, who are at increased risk for CNS toxicity, and for newborns, due to the documented risk of hyperbilirubinaemia.

Therapeutic Uses of Luf

What Luf Treats: Main Uses and Benefits

Luf (Flucloxacillin) is commonly used to help manage bacterial infections that fall within several key symptomatic and therapeutic domains. Its primary therapeutic benefit is to provide supportive relief against susceptible bacteria, which contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods. The drug is indicated for a wide range of infections caused by sensitive Gram-positive organisms.

It is generally applied in addressing conditions presenting with localized discomfort and symptoms related to inflammatory or irritative states on the skin and underlying tissues. The conditions most often associated with its use include cellulitis, abscesses, boils, impetigo, infected wounds, osteomyelitis, and septicaemia. The medication plays a role in managing symptom clusters that may become intense or disruptive, such as noticeable redness, swelling, and pain at the infection site.

Luf is also used in specific clinical contexts, such as prophylaxis (infection prevention) during major surgeries and for treating infections in the paediatric population.

Quick Fact: Relief for Inflammation
Luf may assist with the management of symptoms associated with active inflammation, such as local swelling and warmth, by targeting the underlying bacterial cause.

Eligibility and Restrictions for Use

Who can and cannot use Luf?

The eligibility for Luf (Flucloxacillin) is strictly defined by regulatory documents, establishing absolute prohibitions and specific restrictions for certain populations.

Absolute Contraindications (Must Not Use)

Use is contraindicated if a patient has a documented history of hypersensitivity to β-lactam antibiotics (including penicillins). The medicine is also prohibited for patients with a previous history of Flucloxacillin-associated jaundice or hepatic dysfunction, or a prior diagnosis of Acute Generalised Exanthematous Pustulosis (AGEP).

Restricted Use Populations (Use with Caution)

Specific caution is required for patients with co-existing conditions, including those with evidence of hepatic dysfunction, Porphyria, or a serious underlying disease. Use is conditional for those with severe renal impairment (Creatinine Clearance < 10 mL/min), which may require special consideration.

Age and Life State Restrictions

The label specifies conditional use for certain age groups, noting that newborns and neonates require special caution due to the risk of hyperbilirubinaemia. Use is also conditional for pregnant women (only if benefits outweigh risks) and breastfeeding mothers (discontinuation may be necessary), as well as patients over 50 years of age due to an increased risk of hepatic reactions.

What should I know about interactions with other medicines?

Luf Interactions with other medicines and products

Luf is a substrate for both the CYP3A4 metabolic enzyme and the P-glycoprotein (P-gp) efflux transporter. This dual dependency forms the mechanistic basis of its major drug interactions, where co-administered medicines can significantly alter Luf’s plasma concentrations.

Interacting Product Category Effect on Luf’s Concentration Regulatory Recommendation
Strong CYP3A4 and P-gp Inhibitors (e.g., Ritonavir, Itraconazole) Increased (risk of toxicity) Dose reduction of Luf is required; close monitoring is mandatory.
P-gp Inhibitors (e.g., Quinidine) Increased (risk of central effects) Use with caution at recommended dosages.
CYP3A4 Inducers (e.g., Phenytoin, Rifampin) Decreased (risk of loss of efficacy) Concomitant use is generally not recommended.
Drugs that Prolong the QT Interval (e.g., Amiodarone, Citalopram) Increased risk of QTc prolongation Use with caution; monitor for serious cardiac adverse reactions.

Luf is also a weak P-gp inhibitor, which may lead to increased concentrations of other co-administered medicinal products that are substrates of P-gp (e.g., Saquinavir). This effect can reduce the therapeutic efficacy of the P-gp substrate. Patients with existing risk factors for cardiac arrhythmias should exercise particular caution with Luf, especially when taking other QT-prolonging medicines.

Mechanism of Action

Irreversible Blockade of Bacterial Cell Wall Assembly

The active molecule, Flucloxacillin, functions as an irreversible, mechanism-based inhibitor by targeting crucial enzymes on the bacterial membrane known as Penicillin-Binding Proteins (PBPs). The drug’s core structure covalently binds to and inactivates these PBPs, preventing the final, essential cross-linking step in the synthesis of the rigid peptidoglycan cell wall. This molecular failure prevents the formation of a stable protective layer, triggering the bacterium's own autolytic enzymes, which together lead to lysis and the bactericidal (cell-killing) effect.

Mechanistic Protection Against Beta-Lactamase

A key mechanistic feature of Flucloxacillin is its engineered resistance to certain bacterial defense enzymes. The molecule contains a bulky chemical side chain that creates steric hindrance, physically shielding the drug's active site (the beta-lactam ring) from destruction by beta-lactamases (penicillinases). This protection preserves the drug's integrity, allowing it to remain functional to execute its primary mechanism against the PBP targets.

Constraint by Target Site Modification

The drug's mechanism is fundamentally limited by target site modification. Against bacterial strains such as MRSA, the organism synthesizes a modified enzyme, PBP2a, which has a significantly reduced affinity for Flucloxacillin. Because the drug cannot achieve the required high-affinity binding to this altered target, the necessary cascade of cell wall inhibition and subsequent lysis cannot be initiated, rendering the mechanism ineffective in these specific biological contexts.

Dosage and Administration Information

How to Use Luf: Administration Guidelines

Luf (Flucloxacillin) is used according to established procedures which define the correct method, frequency, and dose adjustments for the medicine. Its administration is available via multiple routes, including oral (capsules, liquid), intramuscular (IM), and intravenous (IV) injection or infusion.

Administration Timing and Conditions

To ensure optimal absorption, oral Luf must be taken on an empty stomach, specifically at least one hour before or two hours after a meal. The medicine should be swallowed with a full glass of water (about 250 ml), and the patient should not lie down immediately after intake to avoid procedural discomfort.

Standard Dosing and Frequency

Administration Type Standard Adult Dose Frequency Special Consideration
Oral (Capsules) 250 mg to 500 mg Four times daily (QID) Doses may be doubled in severe infections.
Parenteral (IV/IM) 250 mg to 1 g Every six hours (Q6H) IV injection must be slow, over 3 to 4 minutes.
High-Dose (IV) Up to 8 g daily Divided doses, 6 to 8 hourly Max dose 12 g daily; maximum single IV dose is 2 g.

Population-Specific Use

Dosage requires modification for the paediatric population and those with impaired kidney function. Paediatric doses are standardized based on the adult dose, with children 2 to 10 years typically receiving half the adult dose. In cases of severe renal failure (creatinine clearance <10 mL/min), a reduction in dose or extension of the dose interval is required, with a maximum recommended dose often set at 1 g every 8 to 12 hours. Luf is not significantly removed by dialysis, meaning no supplementary dose is generally required during or at the end of the dialysis period.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Luf


Evidence for Use in Skin and Soft Tissue Infections (SSTIs)

Clinical research for common skin and soft tissue infections, such as cellulitis and impetigo, has primarily utilized Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies monitored outcomes related to observed changes and symptom patterns. When Luf was evaluated in comparison to alternative antibiotic agents, studies explored whether outcomes showed consistent patterns. However, a majority of the comparative research often uses a non-inferiority design, meaning studies examined whether measured outcomes were comparable to existing treatments. Information on recurrence extending beyond one year is not widely available.


Evidence for Deep-Seated and Systemic Infections

Research related to complex conditions, such as bone infections (osteomyelitis) and bloodstream infections (septicaemia), was evaluated in structured research settings. The evidence base here is characterized by Prospective and Retrospective Cohort Studies, where Luf was observed in specific hospital programs. These studies monitored outcomes reflecting physiological strain or stress, such as survival rates and the persistence of bacteria. The evidence for these complex conditions is heterogeneous, and few data are available for low-frequency patient groups like those with specific severe co-morbidities.


Unanswered Questions and Research Gaps for Luf

Since many trials were structured to confirm that Luf was associated with an outcome comparable to existing treatments, evidence suggests that unique advantages over other treatments are not fully established. Comparative evidence is lacking across every potential alternative, and for more complex conditions, sample sizes were modest. The evidence quality varies across studies, and research must continue to fill in the gaps, especially concerning long-term effects are not well characterized across all populations.

Key Studies & References

  1. NICE Guideline NG14: Cellulitis and erysipelas: antimicrobial prescribing

Frequently Asked Questions (FAQ)

Common questions about Luf (FAQ)


Q: What is the main reason Luf is prescribed?

A: Luf, which contains the antibiotic Flucloxacillin, is prescribed to treat various types of bacterial infections. Regulatory documents confirm its use for infections most commonly found in the skin and soft tissues, such as cellulitis, as well as infections in the bone or bloodstream.


Q: Why do people say Luf makes them tired?

A: Tiredness is listed as a potential side effect in patient information leaflets for Luf, although it is not one of the most common reactions. Additionally, in very rare cases, severe adverse reactions, such as drug-induced anaemia (a reduction in red blood cells), have been associated with symptoms like tiredness and breathlessness.


Q: How soon after starting Luf might I notice a difference?

A: Official information indicates that for most common infections, people taking Luf typically start to feel better within a few days of starting treatment. Following the full course as prescribed is generally indicated, even if symptoms begin to improve sooner.


Q: Is Luf considered a long-term treatment?

A: Regulatory guidelines indicate treatment length may vary based on the infection. While many infections are treated with short courses, official regulatory guidelines recommend regular monitoring of liver and kidney function for prolonged treatments, such as those lasting more than 14 days, due to potential long-term risks.


Q: What happens if I forget to take Luf for a day?

A: Official patient guidance describes the procedure for a missed dose: if a dose is forgotten, it may be taken as soon as it is remembered, unless it is nearly time for the next dose. The procedure is intended to ensure doses remain appropriately spaced out, according to the prescribed schedule. Never take two doses at the same time to make up for a forgotten dose.


Q: Does Luf affect a person's mood or energy levels?

A: Official regulatory lists of common side effects for Luf do not include mood changes. However, severe adverse reactions, such as the very rare occurrence of anaemia (a reduction in red blood cells), have been associated with symptoms that may affect energy, like tiredness or breathlessness.


Q: Is it common to have headaches when first starting Luf?

A: Headaches are listed as a possible, but not common, side effect in patient information leaflets for Luf. If any symptom becomes severe or persistent, regulatory bodies advise seeking consultation with a healthcare professional.


Q: Is Luf available as a generic medicine?

A: Yes, the active ingredient in Luf, Flucloxacillin, is widely available as a generic medicine in many countries. This means that versions of the medicine are produced and sold under its chemical name, not just the specific trade name Luf.


Q: How long does the effect of Luf last after each use?

A: The recommended frequency for taking Luf is typically four times a day or every six hours. This typical dosing frequency reflects the need to maintain adequate concentrations of the medicine in the body to help fight the infection.


Q: Is Luf known to interact with birth control pills?

A: Luf is generally not known to reduce the effectiveness of oral contraceptive pills. However, official guidance notes that if a patient experiences vomiting or severe diarrhoea while taking any antibiotic, this can interfere with the absorption of the pill. If this occurs, regulatory guidance states that supplementary contraception may be necessary.


Q: Is Luf safe to handle for caregivers or family members?

A: Official safety precautions indicate that caution is advised when handling the dry or powder forms of Luf, particularly the powder for injection. Due to the potential for allergic reactions, care in handling the dry or powder forms is advised in official labeling.


Q: What are the ingredients in Luf besides the active component?

A: In addition to the active ingredient Flucloxacillin, Luf contains inactive ingredients, also known as excipients. These can vary by formulation (e.g., capsule or liquid) and may include substances like lactose, sucrose, or sorbitol, which are listed in the official Summary of Product Characteristics (SmPC) for patient safety.


Q: Is it normal to feel dizzy in the first week of taking Luf?

A: Dizziness is listed as a possible, though not common, side effect of Luf in patient information. It is also important to note that very rare but serious adverse reactions, such as anaemia, may also be associated with light-headedness or dizziness.


Q: What should I know about taking Luf and driving?

A: Official labeling states that a person experiencing side effects such as dizziness or drowsiness while taking Luf should be advised not to drive or operate machinery. This is a general caution to ensure safety while using the medicine.


Q: Can Luf be stopped suddenly, or does it need to be tapered?

A: Regulatory guidance emphasizes that the full course of Luf treatment should be completed as prescribed. Stopping an antibiotic early, even when symptoms improve, is associated with the risk of infection recurrence and may contribute to bacterial resistance.


Q: Can Luf be taken with common pain relievers?

A: Official regulatory guidance highlights that caution should be used when Luf is taken alongside Paracetamol (Acetaminophen). This combination has been associated with an increased risk of a serious metabolic condition, particularly in patients who have pre-existing risk factors.


Q: Are there any foods or drinks to limit while taking Luf?

A: To ensure optimal absorption, the official guidelines mandate that Luf must be taken on an empty stomach—either one hour before a meal or two hours after. Regulatory bodies state that drinking alcohol is generally acceptable with Luf, and no specific foods are listed for limitation.


Q: Can Luf interact with herbal supplements?

A: Official resources state that there is generally not enough safety information to confirm that herbal remedies and supplements are safe to take with Luf. Official guidance suggests disclosing all supplements and remedies to a healthcare professional.


Q: Is Luf considered a controlled substance?

A: No. Luf, which is Flucloxacillin, is classified as a beta-lactam antibiotic. Official regulatory bodies, such as the US DEA, do not list it as a controlled substance, meaning it does not carry the same legal restrictions for potential misuse and dependence.


Q: Does Luf interact with common supplements like Vitamin D or B12?

A: Regulatory guidance suggests that while most common vitamins and minerals can be taken with antibiotics, some antibiotics and supplements can interact. It is recommended to discuss all supplements with a healthcare professional.


Q: What should I do if I suspect an interaction between Luf and another drug?

A: In the event a person suspects an adverse reaction or a drug interaction, official patient guidance indicates that medical advice should be sought from a healthcare professional or pharmacist. A healthcare professional is the appropriate resource to evaluate the situation.


Q: What does it mean if Luf has a 'Boxed Warning'?

A: A 'Boxed Warning' is the most serious level of safety alert used by regulatory agencies, such as the FDA, to highlight potential serious or life-threatening risks. For Luf, this warning (or its equivalent in other regions) draws attention to the risk of severe liver-related reactions.


Q: Are there any official restrictions on who can prescribe Luf?

A: Luf is designated as a prescription-only medicine, meaning a healthcare professional must authorize its use. In some regions, its supply may also be managed under a Patient Group Direction (PGD), which allows specific trained healthcare staff to legally supply the medicine without an individual written prescription.


Q: What happens to Luf in the body (absorption/elimination)?

A: Official pharmacokinetic data shows that Luf is well-absorbed from the stomach, especially when taken without food. Once in the body, it is primarily eliminated by the kidneys. This elimination is slowed in people with severe kidney impairment, which is why dose adjustments may be necessary.


Q: Do most patients who take Luf experience side effects?

A: Official regulatory documents classify adverse reactions by frequency. The most frequently observed reactions are 'Common,' meaning they are expected to affect between 1 and 10 out of every 100 users, and typically include minor gastrointestinal disturbances like nausea and diarrhoea.


Q: Does Luf interact with common cold or flu medications?

A: Caution is advised regarding cold and flu medications. Regulatory information indicates that certain ingredients in these over-the-counter products, such as those that can affect the heart's electrical activity (prolong the QT interval), may interact with Luf. A healthcare professional can provide guidance on specific combinations.


Q: Is it known if Luf passes into breast milk?

A: Yes, official guidance indicates that only tiny amounts of Luf pass into breast milk. It is considered generally acceptable to take while breastfeeding, but the baby should be monitored for signs of side effects, such as diarrhoea or oral thrush.

How should Luf be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific storage and handling requirements for Luf (Flucloxacillin) to maintain stability.

Item Requirement (Official Labeling)
Dry Form Storage (Capsules/Powder) Store in the original package at a temperature not exceeding 25 C or 30 C and protect from moisture.
Reconstituted Liquid Must be stored in a refrigerator (2 C to 8 C). It must be discarded after its labeled period of use, typically 7 to 14 days.
Child Safety The medicine must be kept out of the sight and reach of children.
Disposal Do not dispose of unused or expired product via household waste or wastewater. Disposal must follow explicit local regulations for pharmaceutical waste.

These mandated conditions ensure the integrity of the product and define proper environmental disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Luf found in:

A-Z Index: